Evofosfamide is primarily used in the field of oncology as a targeted cancer therapy. It is designed to selectively target and destroy cancer cells, particularly in hypoxic (low oxygen) environments, which are common in solid tumors. The compound works as a prodrug, becoming activated under low oxygen conditions to release a potent DNA alkylating agent. This mechanism allows it to effectively damage the DNA of cancer cells, leading to their death while minimizing harm to healthy tissues. Evofosfamide is often explored in combination with other treatments like chemotherapy or radiation to enhance its efficacy, especially in cancers that are resistant to conventional therapies. Its application is particularly significant in treating aggressive and hard-to-treat cancers such as pancreatic cancer, glioblastoma, and soft tissue sarcomas.